ONCE - Adverum: Speculative Gene Therapy Play With In-House Capabilities Targeting The Validated And Attractive Ocular Space
Note: This article was first made available to members of my exclusive community, The Formula, on May 14 when shares of Adverum (ADVM) were trading just over $6.
Read: Adverum's most quarterly filing
Read: ADVM-022 article (preclinical findings)
Gene therapy - opportunity & validation in the ocular space
The gene therapy space was subject to merger & acquisition earlier this year with the likes of Spark (ONCE) & Nightstar (NITE) being acquired. Both companies were developing gene therapies for ocular diseases. The former had developed the first FDA-approved